New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 18, 2012
19:11 EDTMNOVMedicNova extends MN-166 patent position in Europe
MediciNova announced that it has received Notices of Allowance from the European Patent Office, EPO, for two pending patent applications. One covers the use of ibudilast, MN-166, in drug addiction and the other provides for ibudilast use to enhance opioid analgesia in acute pain settings. MN-166 is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, drug addiction, and pain.
News For MNOV From The Last 14 Days
Check below for free stories on MNOV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 7, 2014
19:53 EDTMNOVMedicNova announces new NIDA grant for MN-166 in opioid dependence
MediciNova announced that Columbia University and the New York State Psychiatric Institute was awarded new grant funding from the National Institute on Drug Abuse, NIDA, to continue clinical research on MN-166, ibudilast, in opioid dependence. The new grant will support the completion of a Phase 2a clinical trial of MN-166, ibudilast, in opioid dependence, for which positive interim results were previously reported by MediciNova on August 18. The principal investigator, Dr. Sandra Comer, PhD, Professor of Neurobiology at Columbia University and the New York State Psychiatric Institute commented, "We are honored to receive this grant from NIDA with more than $2.66 MM for the next nine months and to be notified of a potential award of more than $11 MM for the next four years." Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased with NIDA's continued support of clinical research on MN-166 (ibudilast) in opioid dependence. We look forward to additional data as the study advances."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use